July 30, 2020
PledPharma AB (STO: PLED) today announced that Marie Ekström Trägårdh has chosen to step down from the company's Board of Directors due to private reasons.
The duties and responsibilities of the Remuneration Committee and the Audit Committee will from now be taken on by the Board of Directors. Members of both these committees consisted previously of Håkan Åström, Chairman of the Board, and Marie Ekström Trägårdh.
About Us
PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. The phase III program was recently stopped with a data cut-off targeted for the third quarter 2020. The drug candidate Aladote® is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see http://www.pledpharma.com/
